Welcome to California COVID-19 Vaccination Program Friday Provider Office Hours



Friday, February 11, 2022



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at: https://eziz.org/covid/education/



If you have technical difficulties, please contact Rachel.Jacobs@cdph.ca.gov



Agenda: Friday, February 11, 2022

No.	Item	Speaker	Time (AM)
1	Welcome & Announcements	Leslie Amani (Moderator)	9:00 – 9:05
2	Special: Pediatric Rollout	Robert Schechter, M.D., Alan Hendrickson, Claudia Aguiluz (CDPH)	9:05 – 9:25
3	Vaccine Administration	Elizabeth Reosti (CDPH)	9:25 – 9:30
4	Clinical Update	Caterina Liu, M.D. (CDPH)	9:30 – 9:35
	Q&A		9:35 – 9:45
5	Storage & Handling	Alan Hendrickson (CDPH)	9:45 – 9:50
6	Vaccine Management	Eric Norton (My Turn) and Claudia Aguiluz (CDPH)	9:50 – 9:55
7	Wrap Up & Resources	Leslie Amani (Moderator)	9:55 – 10:00
	Q&A		



Announcements

Leslie Amani, CDPH



Upcoming Webinar: Using Social Media to Effectively Communicate about COVID-19 Vaccines

Please join <u>#ThisIsOurShot</u> physicians, Dr. Vicki Chan and Dr. Alex McDonald, for a webinar training for healthcare professionals on using social media to effectively communicate about COVID-19 vaccines!

Objectives:

- Train health care heroes to engage effectively on social media
- Disseminate simple, evidence-based messaging to build vaccine trust and combat misinformation
- Provide sample COVID-19 social media posts as examples for your platforms

When: Wednesday, February 16 at 12:30PM

Register here!






#ThisIsOurShot/#VacunateYa All-Coalition Meeting

Join #TIOS to hear special guest, Dr. Dorit Reiss, discuss vaccine laws/mandates and the barriers we may face in the future.

When: Wednesday, February 16 at 5PM PT

Register here!



COVID Conversations Series

COVID Conversation Program 10

Description:

For Program #10 we are pleased to welcome Dr. Dean Blumberg and Dr. Nava Yegeneh in a short presentation and then conversation about COVID variants, booster doses, vaccination of school age children and more.

The conversation will be moderated by CIC Board member Dr. Pia Pannaraj, Infectious Disease Specialist at Children's Hospital Los Angeles and Dr. Eric Ball of Children's Hospital of Orange County, Primary Care Network.

Register: here

Time February 17, 2022, 6:00PM in Pacific Time (US and Canada)



COVID-19 Defense



Facebook & Instagram:

Make a game plan for #SuperBowl Sunday to keep the whole team safer against COVID-19 and its variants.

- Get Tested Be a team player and test for COVID-19 before and after any game day gatherings.
- Open Windows Play your best defense by keeping windows open for better ventilation and airflow.
- Mask Up Gear up by wearing a mask in settings where it can protect you and others, including indoor public and crowded spaces.
- Stay Home if Sick Don't fumble by exposing loved ones to illness! If you're feeling under the weather, catch the big game at home instead and keep all the party snacks to yourself. Visit Covid19.ca.gov for more safety tips.

Twitter:


Make a game plan for #SuperBowl Sunday to keep the whole team safer against COVID-19 and its variants. Test before and after gatherings, open windows for better ventilation, mask up in indoor public and crowded spaces, & stay home if feeling sick. Learn more at covid19.ca.gov.



Stay informed! Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!





- Answers to provider questions
- Updated weekly: last updated 2/10/2022
- Currently in its 58th iteration!



Q: When is authorization for the Pfizer COVID-19 vaccine for children ages 6 months to 4 years expected?

A: The following information is subject to change: FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to meet on <u>Tuesday</u>, <u>February 15</u>. The CDC's Advisory Committee on Immunization Practices (ACIP) is scheduled to meet on Thursday, February 17. COVID-19 vaccine Providers should be ready to vaccinate children 6 months to 4 years old shortly thereafter, pending FDA authorization, CDC recommendations, and review by <u>the Western States Scientific and Safety Review Workgroup (WSSSRW)</u>.



Q: Can immunocompromised patients who received a COVID-19 vaccine additional dose receive a booster dose?

A: Yes. Moderately and severely immuncompromised people aged 18 and over who completed an mRNA COVID-19 vaccine primary series and received an additional mRNA vaccine dose (Pfizer-BioNTech or Moderna), may receive a single COVID-19 booster dose (preferably with an mRNA vaccine) at least 3 months after completing their additional dose. Moderately or severely immunocompromised people ages 12-17 who received the Pfizer primary series and an additional primary series may receive a single Pfizer COVID-19 vaccine booster dose at least 3 months after completing their additional dose. For further information, please visit Clinical Considerations for COVID-19 Vaccine Booster Doses.

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers.

Providers may also visit California COVID-19 Vaccination Program for information and updates.

Directions: Click on a category to be directed to related FAQs.

Contents

New and Updated FAQs	
Pediatric Providers	
Vaccine Program Management	
Provider Enrollment	
Ordering	1
Distribution/Redistribution	
Vaccine Administration	1
Additional Doses for Immunocompromised	1
Booster Doses	1
Vaccine Storage & Handling	2
Inventory	2
Reporting	2
Costs & Reimbursement	
Communication Resources	2

Provider FAQs on EZIZ, Updated Weekly





COVID-19 Vaccination Program Webinars and Training for Providers

Week of February 14, 2022

Note: Calendar subject to change

	Monday 2/14	Tuesday 2/15	Wednesday 2/16	Thursday 2/17	Friday 2/18
myCAvax					Provider Office Hours 9:00 am – 10:00 am PW: Immunize!
Combined Office Hours and Events	My Turn and myCAvax Office Hours 12 pm – 1 pm		COVID-19 Vaccines: Effective Messaging on Social Media Webinar 12:30 pm – 1:30 pm TIOS All-Coalition Meeting with Dr. Dorit Reiss for a Conversation About Vaccine Laws/Mandates 5:00 pm – 6:00 pm		
Demand .	Release 21 (v. 1/18/22) Intro to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn Or Pro Latest Features in My Turn Pro Pro Pro Pro Pro Pro Pro Pro Pro Pr	ovider 101 Account Enrollment: ganization Application (v. 10/21/2 ovider 101 Account Enrollment: cation Application (v. 10/21/21) ovider Office Hours and MCE Offichived Sessions	(v. 12/20/21) Section B: Recording a Ship (v. 12/20/21)		 Recording an Excursion Event (v. 12/20/21) Recording a Waste Event (v. 12/20/21)

Help

vvebsite: www.eziz.org/covid, FAQs

General email: covidcallcenter@cdph.ca.gov

CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: myturnonboarding@cdph.ca.gov

myCAvax Help Desk Email: myCAvax.HD@accenture.com

Phone: (833) 502-1245



Pediatric Rollout

Robert Schechter, M.D. and Panelists, CDPH





MAKE NO MISTAKE COVID-19 IS A CHILDHOOD ILLNESS



COVID-19 CAN BE SERIOUS FOR KIDS.

Pediatric Vaccine Update

Rob Schechter, M.D., CDPH





4X MORE DEATHSTHAN FLU

800 DEATHS


8,300 HOSPITALIZATIONS

Over 800 children have died from COVID-19 in the US, compared to approximately 200 pediatric flu deaths over the past two years.


About 1 in 3 children hospitalized with COVID-19 in the US were admitted to the ICU, similar to the rate among adults.

11X HIGHER RISK OF HOSPITALIZATION

COVID-19 associated hospitalizations in unvaccinated children are 11x higher than fully vaccinated.










COVID-19 vaccination protects against multisystem inflammatory syndrome in children (MIS-C) among 12–18 year-olds hospitalized during July-December 2021









COVID-19 VACCINATION IS THE BEST PROTECTION AGAINST MIS-C

* Case-control study, 238 patients in 24 pediatric hospitals—20 U.S. states
† 2 doses of Pfizer-BioNTech vaccine received ≥ 28 days before hospital admission

bit.ly/MMWR7102







8.7 million* COVID-19 vaccinations have been given to children ages 5-11 years old

Health check-ins to v-safe completed for over 42,000 children after vaccination[†]

Side effects were common but mild and brief[§]



Pain where shot was given



Fatigue



Headache




Mild side effects are a normal sign the body is building protection



Few myocarditis cases have been reported



Vaccination is the best way to protect children from COVID-19 complications



† V-safe, a voluntary smartphone vaccine safety monitoring system

⁶ After the 2nd dose, about 2/3 children had a local reaction such as arm pain; 1/3 had a reaction beyond the injection site

bit.ly/MMWR705152a1







PEDIATRIC VACCINATION COVERAGE IS LOW, ESPECIALLY FOR CALIFORNIA'S MOST VULNERABLE CHILDREN


65% OF KIDS NOT VACCINATED

Over 65% of California children ages 5-11 years have yet to receive 1 dose of COVID-19 vaccine, leaving most children vulnerable to Omicron and future variants likely to follow.



Disparities in children 5-to-11 years similar pattern, but more extreme than older age groups

1+ dose coverage estimates range from 5-78%






Disparities in children 5-to-11 years similar pattern, but more extreme than older age groups

1+ dose coverage VEM quartile gap of >30%

Percent Coverage for 1+ Doses Among 5 to 11 Year Olds by VEM, Since Nov 1, 2021





Vaccine coming soon for Under-5s!



COVID-19 Vaccine for Ages 6 Months – 4 Years Arriving on Presidents Day?

- 2/1: Pfizer BioNTech submitted EUA application to FDA
- 2/6-7:
 - Media reports
 - HHS Timeline, subject to FDA approval, CDC recommendation



Current Planning Information from CDC

Sequence	Doses US	Doses for CA	Recipients	LHJ Deadline	Doses Arrive
1a	2M	225K (10%)	LHJs, MCEs, Redistributor	2/10	2/21 -
1b	2M	225K (10%)	All Providers	2/17	2/22 -
	1M	125 (6%)	Pharmacies		
2	4M	450K (20%)	All Providers	2/25	3/1 - ?
	1M	125 (6%)	Pharmacies		



Preliminary Product Information from Pfizer

Age group	Cap color	Dose	Doses / vial	Diluent / vial
6M – 4Y	maroon	3 mcg / 0.2 mL	10	2.2 mL
5-11 Y	orange	10 mcg / 0.2 mL	10	1.3 mL
12+ Y	gray	30 mcg / 0.3 mL	6	Do not dilute

Clinical trials of 2 and 3 doses:

- •3-week interval between doses 1 & 2
- •8-week interval between doses 2 & 3
 - Data on third dose is still being collected




Sun	Mon	Tues	Wed	Thur	Fri	Sat
13	14 AM: System open 1b orders from all providers	15 FDA VRBPAC	16 4PM: deadline 1b order approval	17	18 ACIP? Western States?	19
20	21 Presidents Day 1a orders arriving (225K doses)	22 1b orders arriving (225K doses CA + 125K doses pharm)	23	24	25 Threshold 2 top-off (450K doses CA 125K doses pharm)	26
27	28	March 1 T2 orders arriving? (450K doses CA + 125K doses pharm)				



Figure 5

Three In Ten Parents Say They'll Get Their Child Under The Age Of Five Vaccinated ASAP When A COVID-19 Vaccine Is Authorized For Their Age Group

Thinking about your child under the age of 5, once there is a COVID-19 vaccine authorized and available for your child's age group, do you think you will...?



NOTE: Among parents or guardians of children under the age of 5. See topline for full question wording. SOURCE: KFF COVID-19 Vaccine Monitor


KFF COVID-19 Vaccine Monitor



Vaccine coming soon for Under-5s! But where will they get it?




Who will immunize young children?





Who will immunize young children?

Most pharmacies are not a resource for children younger than 3 years!





Vaccine coming soon for Under-5s! But where will they get it?

- Pharmacies with a diminished role
- More primary care providers needed
 - Medical home is a trusted source of care
 - Can counsel hesitant families
 - But will take time to onboard
 - Barriers frequently cited: staffing, others...
- Who can bridge the gaps in the meantime?



Expanding efforts and partnerships

- Expanding ages at
 - LHJ sites
 - School-located clinics
- Expanding access beyond usual patients
- Expanding partners and sites
 - Early education?
 - WIC?
 - Other?



CDPH provider outreach includes...

- Communications
 - Infographic
 - Webinars
 - VFC mailings
- Outreach to providers who haven't ordered
- VFC survey results
- Planning with AAP, CAFP, CMA,
- School Clinic Team
- Bright-spot providers, best practices



Pfizer Pediatric (6 Month – 4 Years, Maroon Cap)

	Current P	Future Product	
Age Indications ^a 12 years and o		5 through 11 years	6 months through 4 years ^d
Vial Cap Color and Label with Color Border	GRAY	ORANGE	MAROON
Preparation	Do Not Dilute	Dilute Before Use	Dilute Before Use
Amount of Diluent Needed per Vial ^b	Do Not Dilute	1.3 mL	2.2 mL
Dose Volume/Dose	0.3 mL/ 30 mcg	0.2 mL/ 10 mcg	0.2 mL/ 3 mcg
Doses per Vial	6 doses per vial	6 doses per vial (after dilution)	
	Storage Conditions		
ULT Freezer (-90°C to -60°C)° 9 months		9 months	9 months
Freezer (-25°C to -15°C) DO NOT STORE		DO NOT STORE	DO NOT STORE
Refrigerator (2°C to 8°C)	Refrigerator (2°C to 8°C) 10 weeks		10 weeks
Room Temperature (8°C to 25°C) 12 hours prior to first puncture (including any thaw time)		12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)
After First Puncture (2°C to 25°C)	Discard after 12 hours		Discard after 12 hours

- Minimum order: 100 doses/AmerisourceBergen
- Ancillary Supply Kits



Ordering and Delivery: Pfizer Pediatric Product for Under 5 Years



Ordering for Pfizer's Pediatric (Ages 6 Months – 4 Years) is *coming soon for CA Providers!*



New product has been added in myCAvax system, and ordering phases are as follows:

- ✓ Phase 1a: Ordering Opened to LHDs/MCEs to place orders by 2/10/2022
- ✓ Phase 1b: Standard Ordering available to all Providers on 2/14/2022 to place orders as part of the Monday Order Cycle. LHDs will be submitting approved orders to CDPH on 2/17/2022
- ✓ Phase 2: Small Ordering will be available as part of the Monday Order
 Cycle for providers, on 2/21/2022

Pre-Order Cadence for Providers: Pfizer COVID-19 Vaccine (6 Months-4 Years)

Monday	Tuesday	Wednesday	Thursday	Friday	
February 7	8	9	10	11	
Vaccine Ordering Thresholds received from CDC	myCAvax special Release (New product configuration)	Pre-Orders Round 1A Opens for LHDs/MCEs/TPR	Place Orders by 4pm (LHD/MCEs & TPR); CDPH Transmits orders to CDC	myCAvax readiness for provider Standard Ordering	
14	15	16	17	18	
Pre-Orders Round 1B Opens for Providers (<i>Standard orders-</i> <i>Min 100 doses</i>)		Place Round 1B Orders by 5pm (Providers)	LHD/MCE Approval of 1B Orders by 4pm; CDPH Transmits orders to CDC	myCAvax readiness for Small Ordering	
21 (Holiday)	22	23	24	25	
Pre-Orders Round 2 Opens for Providers (Standard AND Small Orders)	22	25	24	23	
1A Deliveries* 1B Deliveries*		Anticipated Locally-filled Small Order Fulfillment			
28	1	2	3	4	
Anticipated routine ordering					
schedule.* Provider orders	TPR Fulfillment				
submit by 5pm.	I		1		

President's Day Holiday



Provider Schedule

* Upon FDA EUA approval

continue as scheduled on Wednesdays

and Fridays

^ 1A Sites MUST be available to receive shipments on

Coming Soon: Provider Pfizer Pediatric Product for Under 5 Years

Pre-Orders

- Week of 2/14 (Sequence 1b):
 - myCAvax will be enabled for provider ordering. Standard Orders (100 dose minimum)
 - Providers encouraged to place orders along with other COVID-19 vaccines during Monday, 2/14 order
- Week of 2/21:
 - Small orders will be enabled; Providers may place Standard or Small orders starting 2/21 for local and TPR fulfillment
 - First pre-orders delivered on Monday 2/21 (pending FDA EUA approval)
 - Second wave of orders placed the week of 2/14 (delivered 2/22)
 - LHDs/TPR/MCEs receive initial orders, prepare for small orders
- Week of 2/28
 - TPR/Locally filled orders are shipped/delivered
 - Anticipate routine ordering schedule-Order by 5 pm on Mondays



Pfizer COVID-19 Vaccine Medical Updates & Training Sessions

Date & Time (linked)	Password				
Tuesday, February 15 - 12PM	ZteZvrQ3M25				
Wednesday, February 16 - 9AM	qhJNeDVr372				
Thursday, February 17 - 9AM	niX7fg3xTR3				
Monday, February 21 - 12PM	49cUV886dp3				
Tuesday, February 22 - 12PM	MMeBHKrM326				
More sessions listed! NOTE: All times listed here are P.S.T.					

For providers and immunization staff personnel. Please attend one of these sessions!

Topics include:

- Introduction of Comirnaty (gray cap) formulation
- Vaccine use
- Storage & handling
- Preparation & administration
- Medical updates
- Q&A




Appendix

Metrics and Resources



COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C)

- Usually presents about 2-6 weeks post COVID-19 infection.
- >800 reported in CA to date
- ~1/2 previously healthy
- ~1/2 admitted to ICU
- Co-morbidities include obesity, lung disease, congenital heart disease or other malformation, seizures, or cancer





CDC COVID Data Tracker: MIS-C

COVID-19 is a Childhood Illness

- 4x more deaths than flu
- 11x higher risk of hospitalization for unvaccinated children
- Poorest neighborhoods are far behind
- 65% of kids not vaccinated

MAKE NO MISTAKE COVID-19 IS A CHILDHOOD ILLNESS



COVID-19 CAN BE SERIOUS FOR KIDS.



4X MORE DEATHS THAN FLU


800 DEATHS

8,300 HOSPITALIZATIONS

Over 800 children have died from COVID-19 in the US, compared to approximately 200 pediatric flu deaths over the past two years. About 1 in 3 children hospitalized with COVID-19 in the US were admitted to the ICU, similar to the rate among adults.

11X HIGHER RISK OF HOSPITALIZATION

COVID-19 associated hospitalizations in unvaccinated children are 11x higher than fully vaccinated.






PEDIATRIC VACCINATION COVERAGE IS LOW, ESPECIALLY FOR CALIFORNIA'S MOST VULNERABLE CHILDREN

65% of KIDS NOT VACCINATED

Over 65% of California children ages 5-11 years have yet to receive I dose of COVID-19 vaccine, leaving most children vulnerable to Omicron and future variants likely to follow.



Only about 21% of children in California's poorest neighborhoods are vaccinated against COVID-19 compared to 64% in wealthiest neighborhoods.



Children, ages 5-11 (as of January 26, 2022).



California COVID-19 Vaccination Program

IMM-1415-VFC (1/26/22)



Vaccine Administration Data


Elizabeth Reosti, CDPH



Vaccine Administration Summary

as of February 11, 2022

Total Doses Administered: 70,454,894






Trends in Vaccine Administration

as of February 9, 2022

New Doses Administered 500,000 400,000 200,000 100,000

New Doses Administered (millions)




Week End Date



Booster* Vaccinations

as of February 9, 2022



^{**}Note that 12-17 is the newest eligible age group for booster vaccination.


55% of total eligible** population



+0%

booster

between Q1



% Eligible, Has Received Booster

^{*}Includes Additional Doses


^{**24,279,873} individuals, 12+ years of age, and J&J + 2 months or mRNA + 5 months

Clinical Update

Caterina Liu, M.D., CDPH




COVID-19 Vaccination Associated with Decreased Likelihood of ICU Admission



- Lowest likelihood of ICU admission and death in adults who had received a booster dose
- Vaccination, including boosters, are critical for minimizing the risk of severe outcomes

Boosters Protect Against Infection and Hospitalization

FIGURE 1. Age-adjusted rolling 14-day SARS-CoV-2 cumulative incidence* (A) and hospitalization rates (B), by vaccination status — Los Angeles County, California, November 7, 2021–January 8, 2022





Moderna COVID-19 Vaccine Approval and Recommendation

- The FDA announced the approval of the Moderna Vaccine (Spikevax) on 1/31/2022.
- ACIP 2/4/2022 Meeting:
 - The Moderna Phase 3 clinical trial study reviewed
 - 92% VE against hospitalization up to 5 months after the second dose
 - Several studies of myocarditis after mRNA vaccines were presented and reviewed.
 - Higher than expected rates of myocarditis after 2nd dose in males ages 18 49 years
 - No known vaccine-associated myocarditis deaths
 - The committee voted to recommend the Moderna vaccine for the primary series for individuals ages 18 years and older



REVISED COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

Vaccine	Vaccinat	ion Sc	hedule								
Pfizer-	1st dose		2 nd		3 rd					Booster	
BioNTech			dose		dose					dose*	
(ages 5 years			(21 days		(at leas					(at least 3	
and older)			after		28 days	5				months	
•			1 st dose)		after	co)				after 3rd	
					2nd dos	se)				dose)	
Moderna	1 st dose		2 nd		3	3rd				Boo	oster
(ages 18 years			dos	e	d	dose				dos	e*
and older)			(28 d	ays	(a	at least				(at le	east 3
•			after			28 days				mont	
			1 st do	ose)		fter				after	
					2	2nd dose	2)			dose	9
Janssen	1 st dose			tional				Booster			
(ages 18 years			dose					dose*			
and older)			(at le					(at least 2			
			after	-				months			
			1st do					after			
								additional dose)			

^{*}Any COVID-19 vaccine can be used for the booster dose in people ages 18 years and older, though mRNA vaccines are preferred. For people ages 12–17 years, only Pfizer-BioNTech can be used. People ages 5–11 years should not receive a booster dose.



[†]Only Pfizer-BioNTech or Moderna COVID-19 Vaccine should be used

Revaccination for Certain Sub-Groups

- Current guidance: Limited to recipients of hematopoietic cell transplant (HCT) and chimeric antigen receptor (CAR)-T-cell therapy.
- Revised guidance: Recipients of HCT, CAR-T-cell, or other B-cell depleting therapies
 who received doses of COVID-19 vaccine prior to or during treatment should be
 revaccinated for doses received before or during treatment.
- Based on clinical judgement, revaccination may also be considered once immune competence is regained for people who received COVID-19 vaccine doses during chemotherapy or radiation treatment.



Case-by-Case Decision Making Based on Clinical Judgement

 On a case-by-case basis, providers who care for moderately or severely immunocompromised patients may administer mRNA COVID-19 vaccines outside of the FDA and CDC dosing intervals based on clinical judgement when the benefits of vaccination are deemed to outweigh the potential and unknown risks.




15

Passive Antibody Products

Current guidance

Defer COVID-19 vaccination for:

- 30 days if product used for post exposure prophylaxis
- 90 days if product used for treatment
- No guidance for preexposure prophylaxis



Revised guidance

- No recommended deferral period
- However, tixagevimab/cilgavimab (EVUSHELD™) should be deferred for at least two weeks after vaccination


Benschop, et al. (2021). The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination. *medRxiv*. Preprint. **doi:** https://doi.org/10.1101/2021.12.15.21267605



Interim Clinical Consideration for Use of COVID-19 Vaccines

New look coming with reduction and reorganization for ease of use

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States





v-safe: After Vaccination Health Checker



v-safe provides personalized and confidential health check-ins via text messages and web surveys so you can quickly and easily share with CDC how you, or your dependent, feel after getting a COVID-19 vaccine. This information helps CDC monitor the safety of COVID-19 vaccines in near real time.

Have questions about v-safe or need help?
If you have questions or need assistance with **v-safe**, these resources can help:

- •v-safe Frequently Asked Questions and Troubleshooting
- •Contact live v-safe support:


Available Monday-Friday 8:00 AM – 8:00 PM ET Call 800-CDC-INFO (800-232-4636) TTY 888-232-6348



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Storage & Handling

Alan Hendrickson, CDPH



Pfizer pediatric (6 months - 4 years, maroon cap)

	Current P	Future Product				
Age Indications ^a	12 years and older	5 through 11 years	6 months through 4 years ^d			
Vial Cap Color and Label with Color Border	GRAY	ORANGE 📴	MAROON			
Preparation	Do Not Dilute	Dilute Before Use	Dilute Before Use			
Amount of Diluent Needed per Vial ^b	Do Not Dilute	1.3 mL	2.2 mL			
Dose Volume/Dose	0.3 mL/30 mcg	0.2 mL/10 mcg	0.2 mL/3 mcg			
Doses per Vial	6 doses per vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)			
Storage Conditions						
ULT Freezer (-90°C to -60°C)°	9 months	9 months	9 months			
Freezer (-25°C to -15°C)	DO NOT STORE	DO NOT STORE	DO NOT STORE			
Refrigerator (2°C to 8°C)	10 weeks	10 weeks	10 weeks			
Room Temperature (8°C to 25°C)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)			
After First Puncture (2°C to 25°C)	Discard after 12 hours	Discard after 12 hours	Discard after 12 hours			



What's in a label?

Applicable to the following cap colors:

MAROON (Ages 6 months

Label Characteristics Maroon Cap Ages 6 months through 4 years



If authorized by the FDA, Maroon Cap vaccine vials and cartons you receive will be labeled as Pfizer-BioNTech COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine

Initial shipments of Maroon Cap vials and cartons will have the following label characteristics:

Maroon Cap vaccine requires dilution prior to use

*Maroon Cap vial labels and cartons may state that a vial should be discarded **6 hours** after the first dilution. Results from recent stability studies will supersede the current vial label and support discarding the vaccine after **12 hours** from the time of dilution

IMPORTANT INFORMATION

- The vial and carton labels may state
 2 years to <5 years of age or
 6 months through 4 years of age.
- Vials with labels that state for use in individuals 2 years to <5 years of age can be used for individuals
 6 months through 4 years of age.

*Note: Prior to preparation of the vaccine, please review the EUA Fact Sheet (if authorized by the FDA) as the timeframe for use post-dilution has been extended to 12 hours

Pfizer Medical FOR TRAINING PURPOSES ONLY - THE VACCINE HAS NOT BEEN AUTHORIZED FOR USE IN INDIVIDUALS YOUNGER THAN 5 YEARS OF AGE



Janssen (J&J) Shelf-life Extension

- J&J has requested a shelf-life extension for its Janssen vaccine
 - 5 months
 - FDA expected to announce ruling this month
 - Don't dispose of your Janssen yet
- What's in it for you?
 - No additional federal purchase/no biweekly threshold
 - Shelf-life extension provides a limited supply of Janssen through the summer
 - Once again, don't dispose of your Janssen yet



Vaccine Management

Eric Norton, My Turn and Claudia Aguiluz, CDPH



What's New on My Turn: Release 23 (02/09)*

My Turn Public



- ✓ Flu opt-in option was added during the COVID flow if the clinic has COVID and flu Vaccine Supply.
- ✓ COVID flow was added for individuals who received an initial dose(s) of an international WHO approved vaccine.

My Turn Clinic



- ✓ Live Help Desk Chat was implemented.
- ✓ A Walk-In Booster flow was added for individuals who received an initial dose of an internal WHO approved vaccine.
- Group Scheduling.
- ✓ Improvements were made to the joint flow for COVID and flu vaccination.



Live Chat Feature Launched 2/9 – Release 23




A live Help Desk chat option was launched with Release 23 on 2/9 to ensure help is easily available for you!



The live chat feature is to be used exclusively for technical support for myCAvax and My Turn Clinic.




Just look for this icon to launch the chat!






Live Chat Feature Preview – Vaccine Inventory





Live Chat Feature Preview – Updating Contacts






The New COVID/flu Integrated Flow – Release 23

Till.

The COVID and flu flow was updated to ensure it is easy to confirm **both** appointments in one step!






WHO Approved Vaccine Flow – Release 23


The My Turn Public and Clinic flows were updated so individuals who received a WHO approved vaccine can schedule an appointment and receive doses on My Turn. The flow ensures the

correct timelines are

followed for different

scenarios.







*Additional Dose Appointment

Early Access: Brand-New Vaccine Ordering Screen



139 Providers should have access to the brand-new Vaccine Ordering Screen.




If you are a part of the Early Access group, you should have received a communication on 2/3 and attended a training on 2/7. If you are in this group and need more information, please reach out to: covidcallcenter@cdph.ca.gov.



Remember to give feedback when placing orders!



Early Access: Brand-New Vaccine Ordering Screen





VaccineFinder Reporting Reminder for Providers



You must report your on-hand vaccine supply to VaccineFinder on a daily basis.



Keeping this information current helps LHDs during the Order Review process.



Utilize this <u>Job Aid</u> for more information on reporting vaccine to VaccineFinder and contact the VaccineFinder Help Desk at <u>vaccinefinder@castlighthealth.com</u> or call 855-886-4317 with any issues.



APPENDIX



What's New on My Turn: Release 23 (02/09)

My Turn Public

General Enhancements

- ✓ Flu opt-in option has been added during the COVID flow if the clinic has COVID and flu vaccine supply.
- ✓ Clinics allow patients to opt-in Combo only or Combo + flu flow.
- ✓ COVID flow was added for individuals who received an initial dose(s) of an international WHO approved vaccine.
- ✓ Coded Clinics: Super User/Clinic Admin access.
- ✓ Coded Clinics: List view for previously generated codes.
- ✓ Patient's address is restricted to California when using google validation.
- "Country" field was removed if the user is entering patient address manually.
- ✓ Copy consistency updates for more enhanced user experience.
- ✓ Added a line break between Clinic name and address on Select a location page.
- ✓ Updated Location Availability Deletion process for better walk-in flow validation

My Turn Clinic

General Enhancements

- ✓ A Walk-in Booster flow was added for individuals who received an initial dose of an internal WHO approved vaccine.
- ✓ The Help Desk Live Chat was implemented.
- ✓ The Walk-in Existing Appointments module was updated.
- ✓ A re-design of the Bulk Upload Functionality was implemented.
- ✓ Scheduling Multiple Appointments in Walk-In flow is possible.
- ✓ Group Scheduling copy was updated.
- ✓ Improvements were made to the joint flow for COVID and flu vaccination.



myCAvax - Known Issues - Updated 2/3



Known Issues

Scrollbar Issues on Add Provider Page During Section B Enrollment

We are currently investigating how to re-design the Section B Enrollment screen that Adds Medical Staff so that the clicking out of the Medical 'Title' dropdown does not cause issues when trying to scroll to see all the picklist values.

Phone Number Extension Field on Contact Details

We are adding an additional field within Contact details where users can add a phone number extension.



Workaround/Next Steps

- ✓ Fix: TBD
- ✓ In the meantime, we recommend using your mouse's scroll, trackpad, and/or arrowing through the picklist options for 'Title' instead of clicking and dragging the scroll bar

✓ Fix: 2/24/2022



Wrap-up

Leslie Amani, CDPH



Additional Support

Type of Support	Description	Updated 12.29.21
COVID-19 Provider Call Center	The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical provider COVID-19 response, specifically addressing questions about State program requirements, enrodistribution, including the Vaccine Marketplace.	
	Email: covidcallcenter@cdph.ca.gov	
	Phone: (833) 502-1245, Monday through Friday from 8AM–6PM	
Enrollment Support	For Provider enrollment support, please contact myCAvax Clinic Operations at	
	Email: myCAvaxinfo@cdph.ca.gov	
myCAyey Help Deck	Dedicated staff provide up-to-date information and technical support on the myCAvax system.	
myCAvax Help Desk	Email: myCAvax.HD@Accenture.com	
	 Phone: (833)-502-1245, option 3, Monday through Friday 7AM–7PM, Saturday and Sunday 8AM- 	1PM
	For training opportunities: https://eziz.org/covid/education/	
My Turn Clinic Help Desk	For onboarding support (those in the process of onboarding): myturnonboarding@cdph.ca.gov	
	For technical support with My Turn Clinic for COVID-19 and flu vaccines: MyTurn.Clinic.HD@Acce (833) 502-1245, option 4: Monday through Friday 7AM–7PM, Saturday and Sunday 8AM–1PM.	nture.com or
	For job aids, demos, and training opportunities: flu at https://eziz.org/covid/myturn/flu/ and COVID at https://exiz.org/ and	



Hear it? Clear It.

If you see or hear of any vaccine-related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox.



Trust and Safety Team

Our shared mission is to reduce COVID-19 vaccine hesitancy and increase vaccination across the State of California.



How You Can Help

You are critical in our effort to provide Californians accurate and timely information around COVID-19 vaccination.



Monitor What You See and Hear

Monitor online media and what you hear in your local communities for potential rumors and inaccurate information.

If found, report it to rumors@cdph.ca.gov


Contact



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Thank you!



Monday:

My Turn myCAvax Office Hours
Zoom Link

Next session: Monday, February 14, at 12:00 PM

Friday:

Provider Office Hours

Next session: Friday, February 18

Audio Conference: Register to access

Session Password: Immunize!

Thank you to Provider Office Hours' Planning Team: Leslie Amani, Rachel Jacobs, Hailey Ahmed, Blanca Corona, and Reva Anderson.

